CTOs on the Move

Aminex Therapeutics

www.aminextx.com

 
Aminex Therapeutics, Inc. is focused on bringing its breakthrough discoveries to the clinic to improve the lives of cancer patients.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Aminex Therapeutics raised $50M on 06/20/2018

Similar Companies

Canadian Organic Sprout Company

Canadian Organic Sprout Company is a Belleville, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Acceleron Pharma

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

Trevena

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target G protein coupled receptors, or GPCRs. We are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. We have identified four biased ligand drug candidates: TRV130, an FDA-designated Breakthrough Therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; TRV027 was evaluated in a Phase 2b study for the treatment of acute heart failure; TRV734 has completed phase 1 testing for oral treatment of acute and chronic pain; and TRV250 is in preclinical development for the treatment of migraine. In addition, Trevena has an early stage portfolio of drug discovery programs currently in lead optimization.

Aids Vaccine Advocacy Coalition

Aids Vaccine Advocacy Coalition is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Delfi Diagnostics

Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.